… The N-dealkylation pathway that eventually results in 2-chlorohippuric acid formation also …
likewise, CYP(s) contributing to the N-dealkylation step of ticlopidine have not been identified. …

From 11 studies, a total of 1,792 Caucasian probands with insulin-dependent diabetes
mellitus (IDDM) are analyzed. Antigen genotype frequencies in patients, transmission from …

Diffusion-weighted imaging (DWI) has been at the forefront of cancer imaging since the
early 2000s. Before its application in clinical oncology, this powerful technique had already …

… (n = 85), patients with preexisting renal insufficiency (serum creatinine level, ≥150 μmol per
liter) without diabetes (n = 101), and patients with both diabetes and renal insufficiency (n = …

… the statistical analysis, data interpretation, review and editing; CD Payne did the clinical
study design and operations, data acquisition and interpretation, review and editing; NA Farid …

The aim of the current study is to identify the human cytochrome P450 (P450) isoforms
involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically …

BACKGROUND: The aim of this study was to compare rate of onset, magnitude, and consistency
of platelet inhibition after administration of prasugrel or clopidogrel and to relate platelet …

To determine the interfamilial and intrafamilial variation in the expression of the Bardet–Biedl
syndrome (a form of Laurence–Moon–Biedl syndrome), we looked for the five recognized …

Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation.
Prasugrel's active metabolite (R‐138727) is formed primarily by cytochrome P450 (CYP) 3A …

Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active
metabolite that inhibits the platelet P2Y 12 ADP receptor. In this open‐label, 4‐period crossover …